Arcus Biosciences, Inc.

Other

Joel Worley Beatty

Manmohan Reddy Leleti

Jay Patrick Powers

Brandon Reid Rosen

Debashis Mandal

Jenna Leigh Jeffrey

Kenneth Victor Lawson

Samuel Lawrie Drew

Guillaume Mata

Balint Gal

Artur Karenovich Mailyan

Jaroslaw Kalisiak

Xuelei Yan

Dillon Harding Miles

Rhiannon Thomas-Tran

Erick Allen Lindsey

Anh Thu Tran

Steven Donald Jacob

Matthew Epplin

Kai Yu

Clayton Hardman

Yongli Su

Tezcan Guney

Zhang Wang

Karl T Haelsig

Jeremy Thomas Andre Fournier

Ehesan Ul Sharif

Hyunyoung Moon

Jeremy Fournier

Laurent Debien

Corinne Nicole Foley

Rebecca Louise Grange

Eric Newcomb

Laurent Pierre Paul Debien

Ehesan Ui Sharif

Srinivas Paladugu

Shiwei Qu

Masa Podunavac

Dongdong Liu

Manjunath Lamani

Eric Thomas Newcomb

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Inhibitors of ARG1 and/or ARG2

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.

Compounds as inhibitors of AXL

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

Growing community of inventors

San Mateo, CA, United States of America

Joel Worley Beatty